News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
Astellas Pharma Inc. (JOBS) Fails to Get Injunction vs FDA Over Prograf
August 13, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters -- Japan's Astellas Pharma said on Thursday a U.S. court has rejected its request for an injunction to prevent the Food and Drug Administration from approving generic products to its top-selling Prograf transplant drug.
Twitter
LinkedIn
Facebook
Email
Print
Legal
Astellas Pharma US, Inc.
Novartis
MORE ON THIS TOPIC
Manufacturing
Eli Lilly and Regeneron among 7 companies picked for FDA PreCheck pilot program
July 1, 2026
·
2 min read
·
Nick Paul Taylor
FDA
BIO 2026: FDA’s IND initiative is a step toward normalization after slipshod year
June 25, 2026
·
3 min read
·
Jef Akst
Duchenne muscular dystrophy
REGENXBIO bets on FDA flexibility with filing plans for Duchenne gene therapy
June 24, 2026
·
2 min read
·
Gabrielle Masson
Policy
BIO 2026: US public health as we know it is gone. Can we rebuild a better system?
June 23, 2026
·
4 min read
·
Jef Akst